Early Treatment Benefits of Ropinirole Prolonged Release in Parkinson's Disease Patients with Motor Fluctuations
Identifieur interne : 002678 ( Main/Merge ); précédent : 002677; suivant : 002679Early Treatment Benefits of Ropinirole Prolonged Release in Parkinson's Disease Patients with Motor Fluctuations
Auteurs : Bonnie P. Hersh [États-Unis] ; Nancy L. Earl [États-Unis] ; Robert A. Hauser [États-Unis] ; Mark Stacy [États-Unis]Source :
- Movement disorders [ 0885-3185 ] ; 2010.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
We performed a retrospective analysis of the Efficacy And Safety Evaluation in Parkinson's Disease (EASE-PD) Adjunct Study, assessing the minimum time to symptom improvement after initiation of ropinirole prolonged release (2-24 mg/day) versus placebo in patients with moderate-to-advanced PD not optimally controlled with levodopa. Ropinirole prolonged release was superior to placebo at Week 2 for change from baseline in "off" time (adjusted mean treatment difference [AMTD] - 0.7 hours; 95% confidence interval [CI], -1.1, -0.2; P = 0.0029), and "on" time without troublesome dyskinesia (0.4 hours; 95%CI, 0.01, 0.88; P = 0.0444). At Week 4, improvements were seen in change from baseline in Unified Parkinson's Disease Rating Scale total motor score (AMTD, -3.1; 95%CI, -4.4, -1.8; P < 0.0001), activities of daily living score (AMTD, -1.1; 95%CI, -1.7, - 0.5 ; P = 0.0004), and the cardinal symptoms of PD compared with placebo. These analyses indicate that once-daily, adjunctive ropinirole prolonged release can offer PD symptom control 2 weeks after treatment initiation.
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000B21
- to stream PascalFrancis, to step Curation: 002198
- to stream PascalFrancis, to step Checkpoint: 000A91
Links to Exploration step
Pascal:10-0288331Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Early Treatment Benefits of Ropinirole Prolonged Release in Parkinson's Disease Patients with Motor Fluctuations</title>
<author><name sortKey="Hersh, Bonnie P" sort="Hersh, Bonnie P" uniqKey="Hersh B" first="Bonnie P." last="Hersh">Bonnie P. Hersh</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Harvard Vanguard Medical Associates</s1>
<s2>Boston Massachusetts</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Boston Massachusetts</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Earl, Nancy L" sort="Earl, Nancy L" uniqKey="Earl N" first="Nancy L." last="Earl">Nancy L. Earl</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Clinical Neurosciences, GlaxoSmithKline</s1>
<s2>Research Triangle Park, North Carolina</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Neurology, University, of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Division of Neurology, Department of Medicine, Duke University</s1>
<s2>Durham, North Carolina</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0288331</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0288331 INIST</idno>
<idno type="RBID">Pascal:10-0288331</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000B21</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002198</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000A91</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Hersh B:early:treatment:benefits</idno>
<idno type="wicri:Area/Main/Merge">002678</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Early Treatment Benefits of Ropinirole Prolonged Release in Parkinson's Disease Patients with Motor Fluctuations</title>
<author><name sortKey="Hersh, Bonnie P" sort="Hersh, Bonnie P" uniqKey="Hersh B" first="Bonnie P." last="Hersh">Bonnie P. Hersh</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Harvard Vanguard Medical Associates</s1>
<s2>Boston Massachusetts</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Boston Massachusetts</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Earl, Nancy L" sort="Earl, Nancy L" uniqKey="Earl N" first="Nancy L." last="Earl">Nancy L. Earl</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Clinical Neurosciences, GlaxoSmithKline</s1>
<s2>Research Triangle Park, North Carolina</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Neurology, University, of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Division of Neurology, Department of Medicine, Duke University</s1>
<s2>Durham, North Carolina</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Evaluation scale</term>
<term>Fluctuations</term>
<term>Human</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Release</term>
<term>Ropinirole</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du système nerveux</term>
<term>Traitement</term>
<term>Ropinirole</term>
<term>Libération</term>
<term>Homme</term>
<term>Fluctuation</term>
<term>Echelle d'évaluation</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We performed a retrospective analysis of the Efficacy And Safety Evaluation in Parkinson's Disease (EASE-PD) Adjunct Study, assessing the minimum time to symptom improvement after initiation of ropinirole prolonged release (2-24 mg/day) versus placebo in patients with moderate-to-advanced PD not optimally controlled with levodopa. Ropinirole prolonged release was superior to placebo at Week 2 for change from baseline in "off" time (adjusted mean treatment difference [AMTD] - 0.7 hours; 95% confidence interval [CI], -1.1, -0.2; P = 0.0029), and "on" time without troublesome dyskinesia (0.4 hours; 95%CI, 0.01, 0.88; P = 0.0444). At Week 4, improvements were seen in change from baseline in Unified Parkinson's Disease Rating Scale total motor score (AMTD, -3.1; 95%CI, -4.4, -1.8; P < 0.0001), activities of daily living score (AMTD, -1.1; 95%CI, -1.7, - 0.5 ; P = 0.0004), and the cardinal symptoms of PD compared with placebo. These analyses indicate that once-daily, adjunctive ropinirole prolonged release can offer PD symptom control 2 weeks after treatment initiation.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Caroline du Nord</li>
<li>Floride</li>
</region>
</list>
<tree><country name="États-Unis"><noRegion><name sortKey="Hersh, Bonnie P" sort="Hersh, Bonnie P" uniqKey="Hersh B" first="Bonnie P." last="Hersh">Bonnie P. Hersh</name>
</noRegion>
<name sortKey="Earl, Nancy L" sort="Earl, Nancy L" uniqKey="Earl N" first="Nancy L." last="Earl">Nancy L. Earl</name>
<name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002678 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 002678 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Merge |type= RBID |clé= Pascal:10-0288331 |texte= Early Treatment Benefits of Ropinirole Prolonged Release in Parkinson's Disease Patients with Motor Fluctuations }}
This area was generated with Dilib version V0.6.23. |